Reactivation of occult hepatitis B virus infection in patients with rheumatic diseases: pathogenesis, risk assessment and prevention

Masaru Kato; Tatsuya Atsumi

doi:10.1007/s00296-015-3395-x

Reactivation of occult hepatitis B virus infection in patients with rheumatic diseases: pathogenesis, risk assessment and prevention

Masaru Kato^*, Tatsuya Atsumi

^*Corresponding author for this work

Internal Medicine （1）

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

Over the past decade, reactivation of occult hepatitis B virus (HBV) infection has garnered much attention from rheumatologists owing to a number of reports which have indicated the potential risk of biologics in causing this previously ignored infectious complication. Hepatitis due to reactivation of occult HBV infection occurs only occasionally but with high mortality upon occurrence, placing us in a clinical dilemma “to address or not to address?” In this review, we discuss how biological and other immunosuppressive therapies increase the risk of developing reactivation of occult HBV infection and attempt to solve this clinical quandary.

Original language	English
Pages (from-to)	635-641
Number of pages	7
Journal	Rheumatology International
Volume	36
Issue number	5
DOIs	https://doi.org/10.1007/s00296-015-3395-x
State	Published - 2016/05/01

Keywords

Biologics
Hepatitis B virus reactivation
Immunosuppressive drugs
Occult hepatitis B virus infection
Rheumatic diseases

ASJC Scopus subject areas

Rheumatology
Immunology and Allergy
Immunology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00296-015-3395-x

Cite this

@article{95c0dcc24aba4fa49d04bce05c39e817,

title = "Reactivation of occult hepatitis B virus infection in patients with rheumatic diseases: pathogenesis, risk assessment and prevention",

abstract = "Over the past decade, reactivation of occult hepatitis B virus (HBV) infection has garnered much attention from rheumatologists owing to a number of reports which have indicated the potential risk of biologics in causing this previously ignored infectious complication. Hepatitis due to reactivation of occult HBV infection occurs only occasionally but with high mortality upon occurrence, placing us in a clinical dilemma “to address or not to address?” In this review, we discuss how biological and other immunosuppressive therapies increase the risk of developing reactivation of occult HBV infection and attempt to solve this clinical quandary.",

keywords = "Biologics, Hepatitis B virus reactivation, Immunosuppressive drugs, Occult hepatitis B virus infection, Rheumatic diseases",

author = "Masaru Kato and Tatsuya Atsumi",

note = "Publisher Copyright: {\textcopyright} 2015, Springer-Verlag Berlin Heidelberg.",

year = "2016",

month = may,

day = "1",

doi = "10.1007/s00296-015-3395-x",

language = "英語",

volume = "36",

pages = "635--641",

journal = "Rheumatology International",

issn = "0172-8172",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "5",

}

TY - JOUR

T1 - Reactivation of occult hepatitis B virus infection in patients with rheumatic diseases

T2 - pathogenesis, risk assessment and prevention

AU - Kato, Masaru

AU - Atsumi, Tatsuya

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Over the past decade, reactivation of occult hepatitis B virus (HBV) infection has garnered much attention from rheumatologists owing to a number of reports which have indicated the potential risk of biologics in causing this previously ignored infectious complication. Hepatitis due to reactivation of occult HBV infection occurs only occasionally but with high mortality upon occurrence, placing us in a clinical dilemma “to address or not to address?” In this review, we discuss how biological and other immunosuppressive therapies increase the risk of developing reactivation of occult HBV infection and attempt to solve this clinical quandary.

AB - Over the past decade, reactivation of occult hepatitis B virus (HBV) infection has garnered much attention from rheumatologists owing to a number of reports which have indicated the potential risk of biologics in causing this previously ignored infectious complication. Hepatitis due to reactivation of occult HBV infection occurs only occasionally but with high mortality upon occurrence, placing us in a clinical dilemma “to address or not to address?” In this review, we discuss how biological and other immunosuppressive therapies increase the risk of developing reactivation of occult HBV infection and attempt to solve this clinical quandary.

KW - Biologics

KW - Hepatitis B virus reactivation

KW - Immunosuppressive drugs

KW - Occult hepatitis B virus infection

KW - Rheumatic diseases

UR - http://www.scopus.com/inward/record.url?scp=84947093611&partnerID=8YFLogxK

U2 - 10.1007/s00296-015-3395-x

DO - 10.1007/s00296-015-3395-x

M3 - 総説

C2 - 26573663

AN - SCOPUS:84947093611

SN - 0172-8172

VL - 36

SP - 635

EP - 641

JO - Rheumatology International

JF - Rheumatology International

IS - 5

ER -

Reactivation of occult hepatitis B virus infection in patients with rheumatic diseases: pathogenesis, risk assessment and prevention

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this